104 related articles for article (PubMed ID: 23034827)
1. Common management issues in pediatric patients with mild bleeding disorders.
O'Brien SH
Semin Thromb Hemost; 2012 Oct; 38(7):720-6. PubMed ID: 23034827
[TBL] [Abstract][Full Text] [Related]
2. Adenotonsillectomy in patients with desmopressin responsive mild bleeding disorders: a review of the literature.
Dunn AL; Cox Gill J
Haemophilia; 2010 Sep; 16(5):711-6. PubMed ID: 20028423
[TBL] [Abstract][Full Text] [Related]
3. Biological and clinical response to desmopressin (DDAVP) in a retrospective cohort study of children with low von Willebrand factor levels and bleeding history.
Sánchez-Luceros A; Meschengieser SS; Woods AI; Chuit R; Turdó K; Blanco A; Lazzari MA
Thromb Haemost; 2010 Nov; 104(5):984-9. PubMed ID: 20886181
[TBL] [Abstract][Full Text] [Related]
4. Haemostasis prophylaxis using single dose desmopressin acetate and extended use epsilon aminocaproic acid for adenotonsillectomy in patients with type 1 von Willebrand disease.
Santoro C; Hsu F; Dimichele DM
Haemophilia; 2012 Mar; 18(2):200-4. PubMed ID: 21771208
[TBL] [Abstract][Full Text] [Related]
5. Hyponatremia after desmopressin (DDAVP) use in pediatric patients with bleeding disorders undergoing surgeries.
Sharma R; Stein D
J Pediatr Hematol Oncol; 2014 Aug; 36(6):e371-5. PubMed ID: 24942016
[TBL] [Abstract][Full Text] [Related]
6. Desmopressin (DDAVP) in the management of patients with congenital bleeding disorders.
Leissinger C; Carcao M; Gill JC; Journeycake J; Singleton T; Valentino L
Haemophilia; 2014 Mar; 20(2):158-67. PubMed ID: 23937614
[TBL] [Abstract][Full Text] [Related]
7. How do you treat bleeding disorders with desmopressin?
Ozgönenel B; Rajpurkar M; Lusher JM
Postgrad Med J; 2007 Mar; 83(977):159-63. PubMed ID: 17344569
[TBL] [Abstract][Full Text] [Related]
8. Intranasal desmopressin (Octim): a safe and efficacious treatment option for children with bleeding disorders.
Khair K; Baker K; Mathias M; Burgess C; Liesner R
Haemophilia; 2007 Sep; 13(5):548-51. PubMed ID: 17880442
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of high concentration intranasal and intravenous desmopressin in pediatric patients with mild hemophilia A or mild-to-moderate type 1 von Willebrand disease.
Gill JC; Ottum M; Schwartz B
J Pediatr; 2002 May; 140(5):595-9. PubMed ID: 12032528
[TBL] [Abstract][Full Text] [Related]
10. An evaluation of the DDAVP infusion test with PFA-100 and vWF activity assays to distinguish vWD types in children.
Akin M; Karapinar DY; Balkan C; Ay Y; Kavakli K
Clin Appl Thromb Hemost; 2011 Oct; 17(5):441-8. PubMed ID: 20460340
[TBL] [Abstract][Full Text] [Related]
11. Desmopressin--a nontransfusional form of prevention of postextractive bleeding in some patients with von Willebrand's type I disease. Case report.
Rahnama M; Tomaszewski T; Swiatkowski W
Ann Univ Mariae Curie Sklodowska Med; 2002; 57(1):150-3. PubMed ID: 12898917
[TBL] [Abstract][Full Text] [Related]
12. Desmopressin (DDAVP) in bleeding disorders of childhood.
Sutor AH
Semin Thromb Hemost; 1998; 24(6):555-66. PubMed ID: 10066151
[TBL] [Abstract][Full Text] [Related]
13. Incidence of bleeding complications in pediatric patients with type 1 von Willebrand disease undergoing adenotonsillar procedures.
Witmer CM; Elden L; Butler RB; Manno CS; Raffini LJ
J Pediatr; 2009 Jul; 155(1):68-72. PubMed ID: 19394040
[TBL] [Abstract][Full Text] [Related]
14. Haemostatic management of intraoral bleeding in patients with von Willebrand disease.
Morimoto Y; Yoshioka A; Sugimoto M; Imai Y; Kirita T
Oral Dis; 2005 Jul; 11(4):243-8. PubMed ID: 15984956
[TBL] [Abstract][Full Text] [Related]
15. Administration of the vasopressin analog desmopressin for the management of bleeding in rectal cancer patients: results of a phase I/II trial.
Iseas S; Roca EL; O'Connor JM; Eleta M; Sanchez-Luceros A; Di Leo D; Tinelli M; Fara ML; Spitzer E; Demarco IA; Ripoll GV; Pifano M; Garona J; Alonso DF
Invest New Drugs; 2020 Oct; 38(5):1580-1587. PubMed ID: 32166534
[TBL] [Abstract][Full Text] [Related]
16. Desmopressin (DDAVP) for treatment of disorders of hemostasis.
Mannucci PM
Prog Hemost Thromb; 1986; 8():19-45. PubMed ID: 3104987
[TBL] [Abstract][Full Text] [Related]
17. Bleeding tendency and efficacy of anti-haemorrhagic treatments in patients with type 1 von Willebrand disease and increased von Willebrand factor clearance.
Castaman G; Tosetto A; Federici AB; Rodeghiero F
Thromb Haemost; 2011 Apr; 105(4):647-54. PubMed ID: 21264446
[TBL] [Abstract][Full Text] [Related]
18. von Willebrand disease in the pediatric and adolescent population.
Mikhail S; Kouides P
J Pediatr Adolesc Gynecol; 2010 Dec; 23(6 Suppl):S3-10. PubMed ID: 20934894
[TBL] [Abstract][Full Text] [Related]
19. A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease.
Jilma B; Paulinska P; Jilma-Stohlawetz P; Gilbert JC; Hutabarat R; Knöbl P
Thromb Haemost; 2010 Sep; 104(3):563-70. PubMed ID: 20589313
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of desmopressin effects on haemostasis in children with congenital bleeding disorders.
Hanebutt FL; Rolf N; Loesel A; Kuhlisch E; Siegert G; Knoefler R
Haemophilia; 2008 May; 14(3):524-30. PubMed ID: 18284449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
